阿司匹林肠溶片与氯吡格雷联用治疗冠心病的疗效分析

Objective Analysis of the clinical application value of aspirin enteric-coated tablets combined with clopidogrel in the treatment of patients with coronary heart disease. Methods A total of 86 patients with coronary heart disease were included in the study from May 2023 to May 2025. They were randomly divided into two groups using a random number table method: a control group of 43 cases and an observation group of 43 cases. All patients received symptomatic antihypertensive and blood glucose control treatment based on their underlying disease conditions. The control group was also treated with aspirin enteric-coated tablets, while the observation group received symptomatic treatment in combination with aspirin enteric-coated tablets and clopidogrel. The treatment period was 8 weeks, and then the effective rate of treatment, cardiac function index and angina pectoris attack, coagulation index and analyze adverse reactions. Results In terms of therapeutic effect, the total data of the observation group was significantly higher(P<0.05). After treatment, the left ventricular ejection fraction(LVEF) of the two groups increased, the left ventricular end diastolic diameter(LVEDD) decreased, and the attack of angina pectoris improved, but the observation group showing a more significantly improvement(P<0.05). After treatment, prothrombin time(PT) and activated partial thromboplastin time(APTT) in the observation group were longer than those in the control group and the platelet aggregation rate decreased compared to the control group(P<0.05). There was no significant difference in the data comparison of adverse reactions between groups(P>0.05). Conclusion The combination of aspirin enteric-coated tablets and clopidogrel in the antiplatelet therapy of patients with coronary heart disease can promote the recovery of cardiac function and relieve angina symptoms, regulate the coagulation function of the body, with reliable efficacy and good safety, and certain clinical application value.